Bioage Labs (BIOA) Stock Price Target 2026

The average analyst price target for Bioage Labs is $40.78, 634.8% above the current price. Of 9 analysts, 7 rate it Buy and 2 Hold. Targets range from $8 to $73. The latest change came on Oct 12, 2026, when UBS initiated coverage of Bioage Labs with a Neutral rating and a $8 price target.

The Average Analyst Price Target for Bioage Labs is $40.78.

Price Target Range — 7 Quarters

Analyst Consensus — 9 Analysts

7Buy

2Hold

Consensus RatingBuy# Analysts9Avg. Consensus PT$40.78Upside to Avg. PT+634.8%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Bioage Labs Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	UBS	Alice Nettleton	Initiate	Neutral	$8
Sep 9, 2026	Roth Capital	Adam Walsh	Maintained	Buy	$25
Sep 8, 2026	BTIG	Thomas Shrader	Maintained	Buy	$40
Aug 6, 2026	BTIG	Thomas Shrader	Maintained	Buy	$40
Aug 3, 2026	BTIG	Thomas Shrader	Maintained	Buy	$40
Jul 31, 2026	Needham	Joseph Stringer	PT Cut	Buy	$50→$35
May 27, 2026	Roth Capital	Adam Walsh	Initiate	Buy	$36
May 13, 2026	BTIG	Thomas Shrader	Initiate	Buy	$40
Mar 27, 2026	Needham	Joseph Stringer	Initiate	Buy	$50
Mar 10, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$15→$52
Feb 25, 2026	Oppenheimer	Jay Olson	Initiate	Outperform	$60
Feb 18, 2026	Jefferies	Roger Song	Upgrade	Hold→Buy	$9→$62
Jan 27, 2026	Piper Sandler	Yasmeen Rahimi	Initiate	Overweight	$73
Dec 8, 2025	Morgan Stanley	Jeffrey Hung	Upgrade	Underweight→Equal-Weight	$5→$12
Oct 29, 2025	Citigroup	Samantha Semenkow	PT Raise	Buy	$10→$15
Oct 22, 2025	Citigroup	Samantha Semenkow	Upgrade	Neutral→Buy	$5→$10
Mar 24, 2025	Citigroup	Samantha Semenkow	PT Cut	Neutral	$7→$5
Mar 7, 2025	Morgan Stanley	Jeffrey Hung	Assumes	Underweight	$5
Feb 28, 2025	William Blair	Andy Hsieh	Initiate	Market Perform	—
Dec 9, 2024	Citigroup	Samantha Semenkow	Downgrade	Buy→Neutral	$45→$7